The biotech company will conduct a Phase II clinical trial of its universal flu vaccine.
BiondVax Pharmaceuticals Ltd. (TASE:BNDX) today announced that the ethics committees of Hadassah Medical Organization and Sourasky Medical Center in Tel Aviv (Ichilov Hospital) have approved the company's Phase II clinical trial to test the safety and immunology of its multimetric universal influenza vaccine.
The study will include 160 men and women aged 18-49. Biondvax believes that the initial trial results will be available by mid-2011.
Biondvax's share price rose 5.6% by early afternoon to NIS 2.33, giving a market cap of NIS 83 million.
Published by Globes [online], Israel business news - www.globes-online.com - on August 17, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010